VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

T. gondii OMPDC/UP mutant vaccine
Vaccine Information
  • Vaccine Name: T. gondii OMPDC/UP mutant vaccine
  • Target Pathogen: Toxoplasma gondii
  • Target Disease: Toxoplasmosis
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • OMPDC gene engineering:
    • Type: Recombinant protein preparation
    • Description: This OMPDC/UP mutant is from Toxoplasma gondii (Fox and Bzik, 2010).
    • Detailed Gene Information: Click Here.
  • UP gene engineering:
    • Type: Gene mutation
    • Description: This OMPDC/UP mutant is from Toxoplasma gondii (Fox and Bzik, 2010).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intraperitoneal injection (i.p.)
Host Response

Mouse Response

  • Persistence: An OMPDC/UP mutant is attenuated in mice (Fox and Bzik, 2010).
  • Efficacy: An OMPDC/UP mutant induces significant protection in mice from challenge with wild type T. gondii (Fox and Bzik, 2010).
References
Fox and Bzik, 2010: Fox BA, Bzik DJ. Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii. Infection and immunity. 2010; 78(9); 3744-3752. [PubMed: 20605980].